Artizan Biosciences

Artizan Biosciences, Inc. (labs in New Haven; HQ in Durham, NC) is based on the discovery made by founders Dr. Richard Flavell, Noah Palm, PhD, and Marcel de Zoete, PhD in Yale’s Department of Immunobiology that they could distinguish certain pathogenic bacteria from the remainder of the intestinal microbiota. The ability to target these specific bacteria could lead to treatment options for a number of digestive disorders as well as other diseases including obesity, autoimmune disease, and a wide variety of skin, lung and central nervous system (CNS) diseases. Elm Street Venture Partner Barry Schweitzer worked closely with the founders to finalize their development plans before Elm Street participated in a Series A financing in late 2016 led by Hatteras Ventures Partners and including several other institutional and strategic investors.